HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy.

AbstractPURPOSE:
The purpose of the study was to report the use of ranibizumab in choroidal neovascularization secondary to punctate inner choroidopathy.
METHODS:
This was a retrospective case series. Clinical notes of 10 patients with choroidal neovascularization secondary to punctate inner choroidopathy were reviewed (mean age, 40.7 years, age range, 25-58 years).
RESULTS:
Previous therapies included photodynamic therapy, posterior sub-Tenon's triamcinolone, oral prednisolone, and intravitreal triamcinolone. Ten eyes in 10 patients underwent a mean of 1.9 ± 1.3 (± standard deviation) injections of antivascular endothelial growth factor (range, 1-5). All 10 patients had a follow-up review of at least 6 months (median, 12.5 ± 9.2 standard deviation; range, 6-34 months). Nine eyes either maintained or improved vision by at least 1 line on the logarithmic of the minimal angle of resolution calculated equivalent chart at least 6 months after the start of treatment with antivascular endothelial growth factor therapy. No ocular or systemic complications were observed.
CONCLUSION:
The role of ranibizumab in choroidal neovascularization in association with punctate inner choroidopathy has been shown to be beneficial in this small group in whom improvement or stabilization of vision was observed in 9 of 10 eyes. Recurrent choroidal neovascularization can occur in these patients, and additional injections of ranibizumab appear to be safe and efficacious.
AuthorsVictor Menezo, Fiona Cuthbertson, Susan M Downes
JournalRetina (Philadelphia, Pa.) (Retina) Vol. 30 Issue 9 Pg. 1400-4 (Oct 2010) ISSN: 1539-2864 [Electronic] United States
PMID20224465 (Publication Type: Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab
Topics
  • Adult
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Choroid Diseases (complications)
  • Choroidal Neovascularization (drug therapy, etiology, physiopathology)
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Ranibizumab
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: